Vancouver, British Columbia / March 7, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news releases of February 21, 2018 and March 5, 2018, it has increased the previously announced private placement of units from 8,500,000 units at $0.08 to 11,500,000 units at $0.08 for total gross proceeds of up to $920,000.
Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each warrant exercisable for a period of 4 years from the date of closing at a price of $0.10 per share.
Finder’s fees may be payable in accordance with the policies of the Exchange. All securities issued in connection with the private placement are subject to a 4-month hold period in Canada.
The private placement proceeds will be used for research on the Company’s site-selective technology for the development of antibody-drug conjugates in its industrial partnerships and for general working capital.
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells. The Company is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
Dr. Randal D. Chase
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements.
This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.